Sensyne Health (SENS)

Sector:

Health Care

Index:

FTSE AIM All-Share

 54.50p
   
  • Change Today:
      0.000p
  • 52 Week High: 187.50
  • 52 Week Low: 39.50
  • Currency: UK Pounds
  • Shares Issued: 128.57m
  • Volume: 9,441
  • Market Cap: £70.07m
  • RiskGrade: 466

Losses widen at Sensyne Health as it announces new agreements

By Josh White

Date: Monday 28 Jan 2019

LONDON (ShareCast) - (Sharecast News) - Clinical artificial intelligence (AI) technology company Sensyne Health announced its interim results for the six months ended 31 October on Monday, reporting cash and cash equivalents of £57.7m at period-end.
The AIM-traded firm said it used £5.7m cash in operating activities, up from £1.9m in 2017, with revenues rising to £0.04m from £0.02m.

Its adjusted operating loss from continuing operations was £5.1m, widening from £2.9m, which the board said reflected the progress the company made in recruitment, and establishing the Sensyne Health business since formation in May 2017.

The reported operating loss was £10.3m, widening from £3.4m.

On the operational front, Sensyne said it undertook continued recruitment to support and progress its increasing commercial activity, which was expected to lead to an increased operating loss for the remainder of the year.

"I am pleased to report strong progress by Sensyne Health in our first reporting period as a public company, achieving a number of important milestones," said chief executive officer Lord Drayson.

"Our business development pipeline is showing good momentum and is on track to meet the objectives set out at our initial public offering."

"The company is in an excellent position to capitalise on the data assets and clinical artificial intelligence capabilities provided by its equity partnerships with NHS Trusts and the University of Oxford in order to meet the growing world-wide demand for data-driven healthcare innovation."

Also on Monday, Sensyne Health announced a number of new deals, including the signing of an agreement with Jefferson Health for the clinical and economic evaluation of its 'GDm-Healthä' digital therapeutic product and generation of curated patient data within a US hospital system.

It also confirmed conditional agreements for two further NHS Trust strategic research agreements, with George Eliot NHS Trust and Wye Valley NHS Trust, for which they would each be issued with £2.5m in ordinary shares in the company at £1.75 per share.

Sensyne also signed a research agreement with the Big Data Institute at the University of Oxford, using its anonymised patient data from its existing SRAs and digital health products, focussed in the field of chronic disease including chronic kidney disease and cardiovascular disease.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Sensyne Health Market Data

Currency UK Pounds
Share Price 54.50p
Change Today 0.000p
% Change 0.00 %
52 Week High 187.50
52 Week Low 39.50
Volume 9,441
Shares Issued 128.57m
Market Cap £70.07m
RiskGrade 466

Sensyne Health Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
11.48% above the market average11.48% above the market average11.48% above the market average11.48% above the market average11.48% above the market average
55.56% above the sector average55.56% above the sector average55.56% above the sector average55.56% above the sector average55.56% above the sector average
Price Trend
67.45% below the market average67.45% below the market average67.45% below the market average67.45% below the market average67.45% below the market average
60.98% below the sector average60.98% below the sector average60.98% below the sector average60.98% below the sector average60.98% below the sector average
Income Not Available
Growth
14.86% above the market average14.86% above the market average14.86% above the market average14.86% above the market average14.86% above the market average
20.00% above the sector average20.00% above the sector average20.00% above the sector average20.00% above the sector average20.00% above the sector average

What The Brokers Say

Strong Buy 2
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 2
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Sensyne Health Dividends

No dividends found

Trades for 17-Feb-2020

Time Volume / Share Price
15:01 129 @ 54.00p
14:36 740 @ 54.00p
14:00 1,000 @ 54.00p
13:48 1,851 @ 54.00p
12:34 2,018 @ 54.00p

Sensyne Health Key Personnel

CEO Paul Drayson
CFO Lorimer Headley

Top of Page